Peptide Testing: How to Verify Purity and Potency
Peptide testing is the only part of this market that produces hard numbers. Everything else, the vendor's reputation, the community consensus, the confident forum post about which supplier is currently good, is inference. A chromatogram is a measurement, and knowing which measurement answers which question is the difference between believing a vial is what the label says and knowing it.
The catch is that the standard tests do not measure the thing most buyers care about. Purity and identity get reported constantly. Quantity, the number that actually determines your dose, is reported far less often, and that gap is where most of the money in this market gets quietly lost.
Why Peptide Testing Exists at All
Research peptides are sold outside the pharmaceutical manufacturing system. There is no batch release authority and no inspector confirming that the powder in a vial matches the sequence on the label. Quality control is entirely voluntary, and the vendor performing it is also the party with a financial interest in the result.
That is not an accusation, it is a structural problem. Even a scrupulous supplier is usually reselling material synthesised several steps up the chain, so their confidence in a batch is only as good as the paperwork that came with it. Testing is how anyone in that chain, including you, converts trust into evidence. Our sourcing guide covers the wider buying process, while this article is specifically about the analytics.
What the Two Core Tests Actually Measure
Almost every COA you will encounter reports one or both of the following. They answer completely different questions and neither is a substitute for the other.
HPLC: Purity
High performance liquid chromatography pushes a dissolved sample through a column that separates molecules by how strongly they stick to the packing material. Different compounds emerge at different times and the detector records each as a peak. The area under the target peak, divided by the total area of all peaks, gives purity as a percentage.
What this catches is incomplete synthesis. Solid phase synthesis builds a chain one amino acid at a time and every coupling step has a small failure rate, producing truncated sequences that are chemically similar to the target and invisible to the eye, but resolve as separate peaks on HPLC. A result of 98 percent means 2 percent of the peptide material present is something other than what you ordered.
What HPLC does not tell you is how much peptide is in the vial. Purity is a ratio, so a vial containing 3mg of extremely clean BPC-157 and a vial containing 10mg of equally clean BPC-157 both test at 99 percent. This is the single most misunderstood point in peptide testing.
Mass Spectrometry: Identity
Mass spectrometry ionises the sample and measures the mass to charge ratio of the fragments, which yields the molecular weight of the compound. Every sequence has a theoretical molecular weight that follows from its amino acid composition, so a measured weight matching the theoretical weight confirms the vial contains the sequence claimed.
This is the test that catches substitution, where a cheaper compound is sold under the name of an expensive one. In practice, outright identity failures are the rarest failure mode in this market, because substituting a different peptide entirely is easy to detect and hard to explain. It still belongs on a COA, and its absence is worth noticing.
Purity Is Not Potency: The Net Peptide Content Problem
Here is the fact that reframes most COAs. Lyophilised peptide powder is not pure peptide by weight, even when its HPLC purity is 99 percent.
After synthesis, a peptide is cleaved from the resin and purified, usually by preparative HPLC using trifluoroacetic acid. What comes out is peptide bound to counterions, plus residual water absorbed from the air by a material that is aggressively hygroscopic. The powder in the vial is therefore a mixture of peptide, salt, and water, and the peptide fraction of that mass is called net peptide content.
For research grade material, net peptide content commonly sits somewhere between 70 and 90 percent. That has an immediate consequence:
| Label | HPLC purity | Net peptide content | Actual peptide delivered |
|---|---|---|---|
| 10mg vial | 99% | 90% | about 8.9mg |
| 10mg vial | 99% | 75% | about 7.4mg |
| 10mg vial | 99% | not stated | unknown |
Two vials with identical, excellent COAs can differ by 20 percent in the compound they deliver, and nothing on either certificate flags the difference. Amino acid analysis is the reference method for measuring net peptide content, and it appears on a small minority of research COAs. Where a vendor states it, that is a meaningful signal.
It also matters for dose calculation. If you work out concentrations from label weight, as the reconstitution guide describes, you are implicitly assuming 100 percent net peptide content. Real doses run modestly lower than the arithmetic suggests, which is one plausible reason protocols sometimes feel weaker than published research would predict.
Reading a Certificate of Analysis Like a Skeptic
A COA is a document, and documents can be produced. These are the fields that carry actual information.
- Lot or batch number. It must match the number printed on the vial in your hand. A COA with no lot number cannot be tied to any production run, so it can be attached to every batch forever.
- Testing laboratory name. A named independent lab is third party evidence. A blank field, or the vendor's own name, is self reported quality control.
- Test date. A report dated well before a product page that has restocked repeatedly since describes material you are not buying.
- The chromatogram itself. A real one shows a labelled time axis, a main peak with a retention time, and any minor peaks at the baseline. A clean image with no axis labels and no numbers is decoration.
- The methods used. Purity by HPLC and identity by mass spectrometry should both be named, with a quantitative assay as a bonus.
The cheapest test of any vendor remains asking for the COA matching the lot currently shipping. It takes one email, and the response separates suppliers more reliably than any review does.
Independent Labs: Sending Your Own Sample
Buyers are not limited to whatever the vendor chooses to publish. Several analytical labs accept samples directly from individuals, and community testing pools have grown around them, most visibly on Reddit where members split the cost of testing a shared batch.
- Cost. Typically 40 to 100 US dollars per sample, depending on whether you order purity alone or add identity and quantitative analysis.
- Turnaround. Commonly one to three weeks, with international shipping usually the slowest part.
- What you send. Normally the sealed vial, so the lab controls handling. Some labs accept a portion of the powder instead.
- What you get back. A PDF report with the chromatogram, purity percentage, mass spectrometry result where ordered, and quantity if requested.
Order the quantitative test if the budget allows. Purity results in this market cluster tightly in the high nineties and rarely surprise anyone, whereas quantity results are where the interesting failures live. Paying to confirm a vial is 99 percent pure, without asking how much of it there is, buys the answer you were already going to get.
One handling note. Peptides degrade with heat, light, and repeated temperature swings, so a vial that spent a week in a hot mailbox may test worse than it left the warehouse. The storage and stability guide covers the conditions that preserve a sample, and they apply just as much to a vial in transit to a lab.
What Test Results Typically Look Like in This Market
Aggregated community testing shows a consistent pattern. Identity failures are rare. Purity failures are uncommon, and when they occur they tend to be marginal rather than catastrophic, results in the low nineties rather than the high nineties. Quantity shortfalls are the common failure, and they concentrate on expensive, high demand compounds where shorting each vial is both profitable and effectively undetectable without a quantitative assay.
That distribution has a clear implication. The vendor question worth asking is not "is your product pure", because almost everyone can answer yes truthfully. It is "how much peptide is in the vial, and who measured it". The same logic applies to any protocol where an unexpectedly weak response is otherwise hard to explain, and our overview of peptide side effects is worth reading alongside this, since an unexpectedly strong response can equally point at a vial that is not what it claims.
Vendors That Publish Lot Matched Testing
Across the suppliers tracked in our 2026 vendor scorecard, three consistently produce lot specific documentation rather than a generic file, and answer technical questions about testing without deflecting.
Apollo Peptide Sciences publishes per lot reports and is the most straightforward of the three to cross check against a vial in hand, as the Apollo review covers. Pantheon Peptides carries the widest catalogue, which makes it the practical option when a protocol needs several compounds from one source, as the Pantheon review discusses. Amino Club tends to be strongest on cost per milligram at comparable stated purity, which makes it a reasonable source for the vial you intend to send off for independent testing yourself.
None of that replaces your own verification. Published testing tells you what a vendor is willing to show. An independent report on the vial you received tells you what you actually bought, and the two are not the same claim.
When Testing Is Worth the Money
Independent testing is not free, and paying 60 dollars to verify a 45 dollar vial is not automatically rational. A reasonable threshold looks like this.
- Worth testing: a first order from a new vendor you intend to keep using, a bulk purchase where one bad batch multiplies across many vials, an expensive compound, or a protocol that produced a conspicuously weaker or stronger response than expected.
- Usually not worth testing: a single cheap vial from a supplier with a long track record and current lot matched third party COAs, where testing costs about what replacing it would.
- Best value overall: joining a group test. Splitting one quantitative assay across several buyers of the same batch produces the same information at a fraction of the cost.
The broader risk picture, including what testing does not catch, is covered in our peptide safety overview.
Key Takeaways
- HPLC measures purity as a ratio and says nothing about how much peptide is in the vial
- Mass spectrometry confirms identity, which is the rarest failure mode in practice
- Net peptide content, typically 70 to 90 percent, means real doses run below label weight
- A COA is only third party evidence if it names an independent laboratory and carries a matching lot number
- Quantitative assays are where the useful surprises are, and they are ordered least often
- Independent testing runs roughly 40 to 100 dollars per sample with a one to three week turnaround
- Group testing splits the cost of the same information across several buyers
Suppliers publishing lot matched COAs
The two scoring highest on lot specific third party testing in the 2026 scorecard.
Apollo Peptide Sciences Pantheon PeptidesFrequently Asked Questions
What does peptide testing actually measure?
Standard peptide testing measures two separate things. HPLC measures purity, meaning what proportion of the peptide material present is the target sequence rather than truncated or degraded fragments. Mass spectrometry confirms identity, meaning that the molecular weight of the main peak matches the theoretical weight of the sequence on the label. A third and less common test, quantitative analysis, measures how much peptide is actually in the vial. Purity and identity say nothing about quantity, which is why underdosed vials frequently carry perfectly clean COAs.
Is 99 percent purity better than 98 percent?
Marginally, and far less than most buyers assume. The difference between 98 and 99 percent HPLC purity is roughly one percent more related substance impurity, which is a smaller practical variable than whether the vial contains the labelled mass at all. Above about 98 percent, the useful questions shift to whether the COA carries a matching lot number, whether an independent lab produced it, and whether quantity was verified.
What is net peptide content and why does it matter?
Lyophilised peptide powder is never pure peptide by weight. It also contains residual water and counterions left over from synthesis and purification, commonly trifluoroacetate or acetate. Net peptide content is the fraction of the powder mass that is genuinely peptide, typically somewhere between 70 and 90 percent for research grade material. A vial holding 10mg of powder at 80 percent net peptide content delivers about 8mg of peptide, so dosing from label weight alone quietly overstates the dose received.
Can I send my own peptide vial to a lab for testing?
Yes. Several independent analytical labs accept samples from individual buyers and will run HPLC purity, mass spectrometry identity, and in some cases a quantitative assay. Turnaround is usually one to three weeks and cost commonly falls in the range of 40 to 100 US dollars per sample depending on which tests are ordered. The lab typically needs the sealed vial or a portion of the powder, and results are returned as a PDF report with the chromatogram included.
Do vendor published COAs mean the peptides are third party tested?
Not automatically. A COA is only third party evidence if an independent laboratory produced it, and the report itself should name that lab. Reports generated in a vendor's own facility, or COAs with the testing laboratory field left blank, are self reported quality control. That is better than nothing, but it is not independent verification, and it is the point at which a lot number cross check becomes the useful test. The sourcing guide covers how to request one properly.
How often are research peptides actually underdosed?
There is no regulator collecting this data, so any precise figure would be invented. What community testing pools consistently show is that identity failures are rare while quantity shortfalls are not, and that the gap is widest on expensive, high demand compounds where shorting a vial by 20 percent is both profitable and invisible. That pattern is the practical argument for treating quantity, rather than purity, as the number worth verifying.